Lisa Salvatore

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Fotios Loupakis, Chiara Cremolini, Gianluca Masi et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini et al. · British Journal of Cancer · 2009 · 561 citations · Full text

Medicine, Genetics, Oncology +17

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C

Marwan Fakih, Lisa Salvatore, Taito Esaki et al. · New England Journal of Medicine · 2023 · 342 citations

Medicine, Oncology, Pharmacotherapy +17

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 270 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

Gianluca Masi, Fotios Loupakis, Lisa Salvatore et al. · The Lancet Oncology · 2010 · 240 citations

Medicine, Oncology, Pharmacology +10